596778 Disclosed is an isolated nucleic acid comprising a polynucleotide sequence which has at least about 70% sequence identity, or about 80%, or about 85%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% to about 100% sequence identity to SEQ ID NO: 243 or SEQ ID NO: 897, or the complement thereof. Further disclosed is the use of a therapeutically effective amount of a fusion protein in the manufacture of a medicament for administering to a subject for treating a glucose regulating peptide related condition wherein the glucose regulating peptide related condition is selected from juvenile diabetes, type I diabetes, type II diabetes, acute hyperglycemia, and chronic hyperglycemia, wherein said administering results in a detectable level of fusion protein in the plasma of a subject for at least about 50 hours after said administering to said subject, wherein the fusion protein comprises a glucose regulating peptide (GP) sequence selected from SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and a peptide that is at least 70% identical to the amino acid sequence of any one of SEQ ID NOS: 4, 6, and 8, wherein the GP is linked to an extended recombinant polypeptide (XTEN) of at least about 200 amino acids residues, wherein the XTEN is characterized in that the sequence exhibits at least 90% sequence identity to an aligned amino acid sequence selected from SEQ ID NO: 191, SEQ ID NO: 195 and SEQ ID NO: 199. SEQ ID NO: 199GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSG
